Nivolumab monotherapy is effective treatment option for relapsed malignant mesothelioma

Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Malignant mesothelioma is intractable cancer, and no phase III trial has yet shown an improvement in overall survival following the standard first-line chemotherapy doublet comprising pemetrexed and cisplatin or carboplatin since it was licensed in 2004.

Professor Dean Fennell, chair of Thoracic Medical Oncology at the University of Leicester in collaboration with Professor Gareth Griffiths and his team at the Southampton Clinical Trials Unit, University of Southampton, UK,

Read More

Consenting for treatment in advance to reduce leaving the hospital against medical advice among patients with addiction

drug addict
Credit: Pixabay/CC0 Public Domain

Patients with substance use disorders (SUDs) being treated for serious medical conditions are more likely to leave the hospital against medical advice (AMA) than those without addiction. A special type of contract with healthcare providers might enable patients to consent in advance to life-saving medical care—even if they later refuse treatment, according to a commentary in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine (ASAM).

The Substance Use Advance Directive (SUAD) “has the potential to greatly improve the current state of treatment for life-threatening comorbid conditions in SUD

Read More

Larger panel finds more gene mutations, treatment targets for leukemia

IMAGE

IMAGE: Drs. Ravindra Kolhe (left) and Vamsi Kota.
view more 

Credit: Kim Ratliff, Augusta University Photographer

AUGUSTA, Ga. (Feb. 1, 2020) – A gene panel that looks for about 10 times the number of cancer-causing genes as panels currently used to diagnose and fine tune treatment for a variety of cancers is effective at identifying problematic genes in the most common leukemia, investigators report.

The 523-gene panel, developed by San Diego-based biotech company Illumina, which includes all genes known to potentially cause cancer, can be readily adopted for use in clinical laboratories to diagnose acute myeloid leukemia, or AML, the

Read More